MultiCell (MCET) 10-Q 15 Oct 13 2013 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Aug. 31, 2013	Oct. 08, 2013
Document Information [Line Items]
Entity Registrant Name	MultiCell Technologies, Inc.
Entity Central Index Key	811779
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Trading Symbol	MCET
Entity Common Stock, Shares Outstanding		2,513,461,835
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Aug-13
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2013

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Aug. 31, 2013	Nov. 30, 2012
ASSETS
Cash and cash equivalents	$178,121	$199,472
Receivable from warrant holder	130,800	0
Other current assets	14,617	11,293
Total current assets	323,538	210,765
Property and equipment, net of accumulated depreciation of $40,561	0	0
Other assets	280	280
Total assets	323,818	211,045
LIABILITIES AND EQUITY (DEFICIENCY)
Accounts payable and accrued expenses	1,085,649	1,106,177
Payable to related party	50,000	50,000
Advance from warrant holder	0	50,000
Convertible debentures	46,596	0
Current portion of deferred revenue	49,318	49,318
Total current liabilities	1,231,563	1,255,495
Non-current liabilities
Convertible debentures	0	56,026
Deferred revenue, net of current portion	461,753	498,741
Derivative liability related to Series B convertible preferred stock	30,587	19,245
Total non-current liabilities	492,340	574,012
Total liabilities	1,723,903	1,829,507
Commitments and contingencies
Equity (Deficiency) MultiCell Technologies, Inc. equity (deficiency)
Preferred stock	0	0
Common stock, $0.01 par value; 3,000,000,000 shares authorized; 2,391,239,613 and 1,349,803,029 shares issued and outstanding at August 31, 2013 and November 30, 2012, respectively	23,912,396	13,498,030
Additional paid-in capital	18,554,395	27,755,595
Accumulated deficit	-43,158,172	-42,254,594
Total MultiCell Technologies, Inc. stockholders' equity (deficiency)	-229,546	-539,134
Noncontrolling interests	-1,170,539	-1,079,328
Total equity (deficiency)	-1,400,085	-1,618,462
Total liabilities and equity (deficiency)	323,818	211,045
Series B Convertible Preferred Stock [Member]
Equity (Deficiency) MultiCell Technologies, Inc. equity (deficiency)
Preferred stock	461,835	461,835
Total equity (deficiency)	461,835	461,835
Series I Convertible Preferred Stock [Member]
Equity (Deficiency) MultiCell Technologies, Inc. equity (deficiency)
Preferred stock	0	0
Total equity (deficiency)	$0	$0

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Aug. 31, 2013	Nov. 30, 2012
Accumulated depreciation, property and equipment (in dollars)	$40,561	$40,561
Undesignated preferred stock, par value (in dollars per share)	$0.01	$0.01
Preferred stock, shares authorized/designated	963,000	963,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized	3,000,000,000	3,000,000,000
Common stock, shares issued	2,391,239,613	1,349,803,029
Common stock, shares outstanding	2,391,239,613	1,349,803,029
Series B Convertible Preferred Stock [Member]
Preferred stock, shares authorized/designated	17,000	17,000
Preferred stock, shares issued	3,448	3,448
Preferred stock, shares outstanding	3,448	3,448
Preferred stock, liquidation value (in dollars)	$470,316	$470,316
Series I Convertible Preferred Stock [Member]
Preferred stock, shares authorized/designated	20,000	20,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended
	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2013	Aug. 31, 2012
Revenue	$12,329	$12,329	$36,988	$36,988
Operating expenses
Selling, general and administrative	207,753	231,953	626,092	649,454
Research and development	95,418	53,694	216,590	276,324
Stock-based compensation	52,945	105,446	175,866	226,162
Total operating expenses	356,116	391,093	1,018,548	1,151,940
Loss from operations	-343,787	-378,764	-981,560	-1,114,952
Other income (expense)
Interest expense	-707	-762	-2,058	-7,424
Change in fair value of derivative liability	-902	60,562	-11,342	104,526
Gain on disposition of equipment	0	1,500	0	1,500
Interest income	36	106	171	593
Total other income (expense)	-1,573	61,406	-13,229	99,195
Net loss	-345,360	-317,358	-994,789	-1,015,757
Less net loss attributable to the noncontrolling interests	-42,264	-22,771	-91,211	-71,841
Net loss attributable to MultiCell Technologies, Inc.	($303,096)	($294,587)	($903,578)	($943,916)
Basic and Diluted Loss Per Common Share (in dollars per share)	($0.00)	($0.00)	($0.00)	($0.00)
Basic and Diluted Weighted-Average Common Shares Outstanding (in shares)	2,105,332,608	1,065,058,664	1,730,465,999	957,413,780

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (DEFICIENCY) (USD $)	Total	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Series B Convertible Preferred Stock [Member]	Series I Convertible Preferred Stock [Member]	Common Stock [Member]
Balance at Nov. 30, 2011	($1,753,599)	$30,064,619	($40,998,344)	($976,978)	$1,349,844	$573,400	$8,233,860
Balance (in shares) at Nov. 30, 2011					11,339	5,734	823,385,986
Issuance of common stock for conversion of 4.75% debentures	7,290	-3,232,076	0	0	0	0	3,239,366
Issuance of common stock for conversion of 4.75% debentures (in shares)					0	0	323,936,571
Issuance of common stock for exercise of warrants	794,610	787,320	0	0	0	0	7,290
Issuance of common stock for exercise of warrants (in shares)					0	0	729,000
Stock-based compensation	226,162	226,162	0	0	0	0	0
Net loss	-1,015,757	0	-943,916	-71,841	0	0	0
Balance at Aug. 31, 2012	-1,741,294	27,846,025	-41,942,260	-1,048,819	1,349,844	573,400	11,480,516
Balance (in shares) at Aug. 31, 2012					11,339	5,734	1,148,051,557
Balance at Nov. 30, 2012	-1,618,462	27,755,595	-42,254,594	-1,079,328	461,835	0	13,498,030
Balance (in shares) at Nov. 30, 2012					3,448	0	1,349,803,029
Issuance of common stock for conversion of 4.75% debentures	9,430	-10,395,506	0	0	0	0	10,404,936
Issuance of common stock for conversion of 4.75% debentures (in shares)					0	0	1,040,493,584
Issuance of common stock for exercise of warrants	1,027,870	1,018,440	0	0	0	0	9,430
Issuance of common stock for exercise of warrants (in shares)					0	0	943,000
Stock-based compensation	175,866	175,866	0	0	0	0	0
Net loss	-994,789	0	-903,578	-91,211	0	0	0
Balance at Aug. 31, 2013	($1,400,085)	$18,554,395	($43,158,172)	($1,170,539)	$461,835	$0	$23,912,396
Balance (in shares) at Aug. 31, 2013					3,448	0	2,391,239,613

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (DEFICIENCY) (Parenthetical)	9 Months Ended
	Aug. 31, 2013	Aug. 31, 2012
Debt Conversion, Original Debt, Interest Rate of Debt	4.75%	4.75%

CONDENSED_CONSOLIDATED_STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
	Aug. 31, 2013	Aug. 31, 2012
Cash flows from operating activities
Net loss	($994,789)	($1,015,757)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation	175,866	226,162
Gain from disposition of equipment	0	-1,500
Interest expense from amortization of discount on convertible debentures	0	5,000
Change in fair value of derivative liability	11,342	-104,526
Changes in assets and liabilities
Grant receivable	0	303,102
Other current assets	-3,324	305
Accounts payable and accrued liabilities	-20,528	28,864
Deferred revenue	-36,988	-36,988
Net cash used in operating activities	-868,421	-595,338
Cash flows from investing activities
Proceeds from disposition of equipment	0	1,500
Net cash provided by investing activities	0	1,500
Cash flows from financing activities
Proceeds from the exercise of stock warrants	1,027,870	794,610
Change in receivable or advance from warrant holder	-180,800	-301,930
Net cash provided by financing activities	847,070	492,680
Net decrease in cash and cash equivalents	-21,351	-101,158
Cash and cash equivalents at beginning of period	199,472	405,327
Cash and cash equivalents at end of period	178,121	304,169
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest	2,142	2,502
Noncash Investing and Financing Activities:
Issuance of common stock for conversion of 4.75% debentures	$9,430	$7,290

CONDENSED_CONSOLIDATED_STATEME4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)	9 Months Ended
	Aug. 31, 2013	Aug. 31, 2012
Debt Conversion, Original Debt, Interest Rate of Debt	4.75%	4.75%

ORGANIZATION_AND_NATURE_OF_OPE

ORGANIZATION AND NATURE OF OPERATIONS, BASIS OF PRESENTATION, AND RECLASSIFICATIONS	9 Months Ended
	Aug. 31, 2013
Accounting Policies [Abstract]
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]
	NOTE 1. ORGANIZATION AND NATURE OF OPERATIONS, BASIS OF PRESENTATION, AND RECLASSIFICATIONS
	ORGANIZATION AND NATURE OF OPERATIONS
	MultiCell Technologies, Inc. (“MultiCell”), has two subsidiaries, Xenogenics Corporation (“Xenogenics”) and MultiCell Immunotherapeutics, Inc. (“MCTI”). MultiCell holds 95.3% of the outstanding shares (on an as-if-converted to common stock basis) of Xenogenics. MultiCell holds approximately 67% of the outstanding shares (on an as-if-converted to common stock basis) of MCTI. As used herein, the “Company” refers to MultiCell, together with Xenogenics and MCTI.
	The Company’s therapeutic development platform includes several patented techniques used to: (i) isolate, characterize and differentiate stem cells from human liver; (ii) control the immune response at transcriptional and translational levels through double-stranded RNA (dsRNA)-sensing molecules such as the Toll-like Receptors (TLRs), RIG-I-like receptor (RLR), and Melanoma Differentiation-Associated protein 5 (MDA-5) signaling; (iii) generate specific and potent immunity against key tumor targets through a novel immunoglobulin platform technology; and (iv) modulate the noradrenaline-adrenaline neurotransmitter pathway. The Company’s medical device development platform is based on the design of a next-generation bioabsorbable stent, the Ideal BioStent™, for interventional cardiology and peripheral vessel applications.
	BASIS OF PRESENTATION
	The accompanying unaudited condensed consolidated financial statements and related notes of MultiCell and its subsidiaries have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial statements. Accordingly, they do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America (“GAAP”) for complete financial statements. In the opinion of management, all adjustments consisting of normal recurring adjustments considered necessary for a fair presentation have been included. It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended November 30, 2012, previously filed with the SEC. The results of operations for the three-month and nine-month periods ended August 31, 2013, are not necessarily indicative of the operating results for the fiscal year ending November 30, 2013. The condensed consolidated balance sheet as of November 30, 2012, has been derived from the Company’s audited consolidated financial statements.
	RECLASSIFICATIONS
	Certain amounts of operating expenses from the condensed consolidated statement of operations for the three months and the nine months ended August 31, 2012, have been reclassified in the current presentation to conform to the presentation of operating expenses for the three months and nine months ended August 31, 2013. These reclassifications had no effect on the total amount of operating expenses, on the amount of net loss, or on the basic and diluted loss per common share for the three months and the nine months ended August 31, 2012.

GOING_CONCERN

GOING CONCERN	9 Months Ended
	Aug. 31, 2013
Going Concern [Abstract]
Going Concern [Text Block]	NOTE 2. GOING CONCERN
	These condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As of August 31, 2013, the Company has operating and liquidity concerns and, as a result of recurring losses, has incurred an accumulated deficit of $43,158,172. The Company will have to raise additional capital in order to initiate Phase IIb clinical trials for MCT-125, its therapeutic product for the treatment of fatigue in multiple sclerosis patients, conduct further research on MCT-465 and MCT-485 for the treatment of primary liver cancer, and initiate clinical trials for Xenogenic’s bioabsorbable, drug eluting stent, the Ideal BioStent™. The Company’s management is evaluating several sources of financing for the Company’s clinical trial program. Additionally, with its strategic shift in focus to therapeutic programs and technologies, management expects the Company’s future cash requirements to increase significantly as it advances the Company’s therapeutic programs into clinical trials. Until the Company is successful in raising additional funds, it may have to prioritize its therapeutic programs and delays may be necessary in some of the Company’s development programs.
	Since March 2008, the Company has operated on working capital provided by La Jolla Cove Investors, Inc. (“LJCI”). As further described in Note 3 to these condensed consolidated financial statements, under the terms of the LJCI Agreement (as defined below), LJCI can convert a portion of the convertible debenture by simultaneously exercising a warrant at $1.09 per share. As of August 31, 2013, there are 4,659,629 shares remaining on the stock purchase warrant and a balance of $46,596 remaining on the convertible debenture. Should LJCI continue to exercise all of its remaining warrants, approximately $5.1 million of cash would be provided to the Company. The LJCI Agreement limits LJCI’s investment to an aggregate ownership that does not exceed 9.99% of the outstanding shares of the Company. The Company expects that LJCI will continue to exercise the warrants and convert the debenture through February 28, 2014, the date that the debenture is due and the warrants expire, subject to the limitations of the LCJI Agreement and the availability of authorized common stock of the Company.
	These factors, among others, create an uncertainty about the Company’s ability to continue as a going concern. There can be no assurance that LJCI will continue to exercise its warrant to purchase the Company’s common stock, or that the Company will be able to successfully acquire the necessary capital to continue its on-going research efforts and bring its products to the commercial market. Management’s plans to acquire future funding include the potential sale of shares of the Company’s common and/or preferred stock, the sale of warrants, and continued sales of the Company’s proprietary media, immortalized cells and primary cells to the pharmaceutical industry. Additionally, the Company continues to pursue research projects, government grants and capital investment. The accompanying condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

CONVERTIBLE_DEBENTURES

CONVERTIBLE DEBENTURES	9 Months Ended
	Aug. 31, 2013
Debt Disclosure [Abstract]
Long-term Debt [Text Block]	NOTE 3. CONVERTIBLE DEBENTURES
	MultiCell entered into a Securities Purchase Agreement with LJCI on February 28, 2007 (the “LJCI Agreement”), pursuant to which MultiCell agreed to sell a convertible debenture to LJCI in the principal amount of $100,000 and originally scheduled to mature on February 28, 2012 (the “Debenture”). On August 16, 2011, MultiCell and LJCI amended the Debenture to extend the maturity date to February 28, 2014. The Debenture accrues interest at 4.75% per year, payable in cash or common stock at the option of LJCI. In connection with the Debenture, MultiCell issued LJCI a warrant to purchase up to 10 million shares of the Company’s common stock (the “LJCI Warrant”) at an exercise price of $1.09 per share, exercisable over the next five years according to a schedule described in a letter agreement dated February 28, 2007. On August 16, 2011, MultiCell and LJCI amended the LJCI Warrant to extend the expiration date to February 28, 2014. Pursuant to the terms of the LJCI Warrant, upon the conversion of any portion of the principal amount of the Debenture, LJCI is required to simultaneously exercise and purchase that same percentage of the warrant shares equal to the percentage of the dollar amount of the Debenture being converted. Therefore, as an example, for each $1,000 of the principal converted, LJCI would be required to simultaneously purchase 100,000 shares under the LJCI Warrant at $1.09 per share.
	The Debenture is convertible at the option of LJCI at any time up to maturity into the number of shares determined by the dollar amount of the Debenture being converted multiplied by 110, minus the product of the Conversion Price (as defined below) multiplied by 100 times the dollar amount of the Debenture being converted, with the entire result divided by the Conversion Price. The “Conversion Price” is equal to the lesser of $1.00 or 80% of the average of the three lowest volume-weighted average prices during the twenty trading days prior to the election to convert. LJCI converted $9,430 and $7,290 of the Debenture into 1,040,493,584 and 323,936,571 shares, respectively, of the Company’s common stock during the nine months ended August 31, 2013 and 2012, respectively. Simultaneously with these conversions, LJCI exercised warrants to purchase 943,000 shares and 729,000 shares of the Company’s common stock during the nine months ended August 31, 2013 and 2012, respectively. Proceeds from the exercise of the warrants were $1,027,870 and $794,610 for the nine months ended August 31, 2013 and 2012, respectively. At times, LJCI makes advances to MultiCell prior to the exercise of warrants. At August 31, 2013 and November 30, 2012, LJCI had advanced $0 and $50,000, respectively, to MultiCell in advance of LJCI’s exercise of warrants. At August 31, 2013 MultiCell had a receivable from LJCI of $130,800 for proceeds from LJCI’s exercise of warrants in excess of advances previously received. This receivable was collected on September 5, 2013.
	As of August 31, 2013, the remainder of the Debenture in the amount of $46,596 could have been converted by LJCI into approximately 5.8 billion shares of the Company’s common stock, which would require LJCI to simultaneously exercise and purchase all of the remaining 4,659,629 shares of the Company’s common stock under the LJCI Warrant at $1.09 per share. As of November 30, 2012, the balance of the Debenture was $56,026. For the Debenture, upon receipt of a conversion notice from the holder, MultiCell may elect to immediately redeem that portion of the Debenture that the holder elected to convert in such conversion notice, plus accrued and unpaid interest. MultiCell, at its sole discretion, has the right, without limitation or penalty, to redeem the outstanding principal amount of the Debenture not yet converted by the holder into common stock, plus accrued and unpaid interest thereon.

SERIES_B_CONVERTIBLE_PREFERRED

SERIES B CONVERTIBLE PREFERRED STOCK	9 Months Ended
	Aug. 31, 2013
Series B Convertible Preferred Stock [Abstract]
Series B Convertible Preferred Stock [Text Block]	NOTE 4. SERIES B CONVERTIBLE PREFERRED STOCK
	The Company’s Board of Directors has the authority, without further action by the stockholders, to issue up to 1,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions of these shares of preferred stock. The Board of Directors originally designated 17,000 shares as Series B convertible preferred stock. The Series B convertible preferred stock does not have voting rights.
	The Series B shares are convertible at any time into shares of the Company’s common stock at a conversion price determined by dividing the purchase price per share of $100 by the conversion price. The conversion price was originally $0.32 per share. Upon the occurrence of an event of default (as defined in the applicable Series B convertible preferred stock purchase agreement), the conversion price of the Series B shares shall be reduced to 85% of the then-applicable conversion price of such shares. The conversion price is subject to equitable adjustment in the event of any stock splits, stock dividends, recapitalizations and the like. In addition, the conversion price is subject to weighted average anti-dilution adjustments in the event the Company sells common stock or other securities convertible into or exercisable for common stock at a per share price, exercise price or conversion price lower than the conversion price then in effect in any transaction (other than in connection with an acquisition of the securities, assets or business of another company, a joint venture and/or the issuance of employee stock options). As a result of the Company issuing shares of its common stock upon conversion of convertible debentures and upon the exercise of warrants both at prices lower than the conversion price of the Series B convertible preferred stock, and due to the Company not paying the Series B dividends on a monthly basis (as discussed below), the conversion price of the Series B convertible preferred stock has been reduced to $0.0124 per share as of August 31, 2013 and to $0.0215 per share as of November 30, 2012. Pursuant to the applicable Series B convertible preferred stock purchase agreement, each investor may only convert that number of shares of Series B convertible preferred stock into that number of shares of the Company’s common stock that does not exceed 9.99% of the outstanding shares of common stock of the Company on the date of conversion.
	Commencing on the date of issuance of the Series B convertible preferred stock until the date a registration statement registering the shares of the Company’s common stock underlying the preferred stock and warrants issued is declared effective by the SEC, the Company was required to pay on each outstanding share of Series B convertible preferred stock a preferential cumulative dividend at an annual rate equal to the product of multiplying $100 per share by the higher of (i) the Wall Street Journal Prime Rate plus 1%, or (ii) 9%. In no event was the dividend rate to be greater than 12% per annum. The dividend was payable monthly in arrears in cash on the last day of each month based on the number of shares of Series B convertible preferred stock outstanding as of the first day of that month. In the event the Company did not pay the Series B convertible preferred dividends when due, the conversion price of the Series B preferred shares was reduced to 85% of the otherwise applicable conversion price. The Company did not pay the required monthly Series B preferred dividends beginning on November 30, 2006, which, in part, caused the conversion price to be reduced. Subsequent to November 30, 2010, the Company received an opinion of outside counsel providing for the removal of the restrictive legend on the Series B convertible preferred stock, which in turn terminated the requirement to accrue the related dividends. Accordingly, no dividends have been accrued since November 30, 2010. Total accrued but unpaid preferred dividends recorded in the accompanying condensed consolidated balance sheets as of August 31, 2013, and as of November 30, 2012, are $290,724 of which $125,516 are recorded in permanent equity with the Series B convertible preferred stock, and $165,208 are recorded as a current liability in accounts payable and accrued expenses.
	The conversion feature which gives the holders of the Series B convertible preferred stock the right to acquire shares of the Company’s common stock is an embedded derivative. As of August 31, 2013 and November 30, 2012, there were 3,448 shares of Series B convertible preferred stock that were convertible into 27,806,452 and 16,037,209 shares of common stock of the Company, respectively. The fair value of the conversion feature was estimated at $30,587 ($0.0011 per share of common stock) and $19,245 ($0.0012 per share of common stock) at August 31, 2013 and November 30, 2012, respectively, and has been estimated using the Black-Scholes option-pricing model using the following assumptions:
		August 31,			May 31,			February 28,			November 30,
		2013			2013			2013			2012
	Fair value of common stock	$	0.0012		$	0.0014		$	0.0038		$	0.0013
	Conversion price of preferred stock	$	0.0124		$	0.0151		$	0.019		$	0.0215
	Risk free interest rate		2.78	%		2.16	%		1.89	%		1.62	%
	Expected life		10 Years			10 Years			10 Years			10 Years
	Dividend yield		-			-			-			-
	Volatility		148	%		148	%		147	%		141	%
	The fair value of the conversion feature increased by $902 and by $11,342 during the three months and the nine months ended August 31, 2013, respectively, which has been recorded as a loss from the change in the fair value of the derivative liability. The fair value of the conversion feature decreased by $60,562 and by $104,526 during the three months and nine months ended August 31, 2012, respectively, which has been recorded as a gain from the change in the fair value of the derivative liability.
	In the event of any dissolution or winding up of the Company, whether voluntary or involuntary, holders of each outstanding share of Series B convertible preferred stock shall be entitled to be paid first in priority out of the assets of the Company available for distribution to stockholders, an amount equal to $100 per share of Series B convertible preferred stock held plus any declared but unpaid dividends. After such payment has been made in full, such holders of Series B convertible preferred stock shall be entitled to no further participation in the distribution of the assets of the Company.

SERIES_I_CONVERTIBLE_PREFERRED

SERIES I CONVERTIBLE PREFERRED STOCK	9 Months Ended
	Aug. 31, 2013
Series I Convertible Preferred Stock [Abstract]
Series I Convertible Preferred Stock [Text Block]	NOTE 5. SERIES I CONVERTIBLE PREFERRED STOCK
	The Company’s Board of Directors has the authority, without further action by the stockholders, to issue up to 1,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions of these shares of preferred stock. The Board of Directors originally designated 20,000 shares as Series I convertible preferred stock. On July 13, 2004, the Company completed a private placement of Series I convertible preferred stock and a total of 20,000 shares were originally sold to accredited investors. As of August 31, 2013 and November 30, 2012, all of the shares of Series I convertible preferred stock have been converted into shares of the common stock of the Company and no shares of the Company’s Series I convertible preferred stock are outstanding.

LICENSE_AGREEMENTS_AND_DEFERRE

LICENSE AGREEMENTS AND DEFERRED REVENUE	9 Months Ended
	Aug. 31, 2013
License Agreements [Abstract]
License Agreements [Text Block]	NOTE 6. LICENSE AGREEMENTS AND DEFERRED REVENUE
	On October 9, 2007, MultiCell executed an exclusive license and purchase agreement (the “Agreement”) with Corning Incorporated (“Corning”) of Corning, New York. Under the terms of the Agreement, Corning has the right to develop, use, manufacture, and sell MultiCell’s Fa2N-4 cell lines and related cell culture media for use as a drug discovery assay tool, including biomarker identification for the development of drug development assay tools, and for the performance of absorption, distribution, metabolism, elimination and toxicity assays (ADME/Tox assays). MultiCell retained and will continue to support its existing licensee, Pfizer, Inc. (“Pfizer”). MultiCell retains the right to use the Fa2N-4 cells for use in applications not related to drug discovery or ADME/Tox assays. MultiCell also retains rights to use the Fa2N-4 cell lines and other cell lines to further develop its Sybiol® liver assist device, to identify drug targets and for other applications related to the Company’s internal drug development programs. Corning paid MultiCell $750,000 in consideration for the license granted. The Company is recognizing the income ratably over a 17 year period. The Company recognized $11,029 and $33,088, respectively, in income for each of the three months and nine months ended August 31, 2013 and 2012. The balance of deferred revenue from this license is $488,971 at August 31, 2013 and will be amortized into revenue through October 2024.
	The Company has another license agreement with Pfizer, for which revenue is being deferred. The Company recognized revenue from the agreement with Pfizer in the amount of $1,300 and $3,900 for the three months and the nine months ended each of August 31, 2013 and 2012, respectively. The balance of deferred revenue from the agreement with Pfizer is $22,100 at August 31, 2013, which will be amortized into revenue through January 2018.

STOCK_COMPENSATION_PLANS

STOCK COMPENSATION PLANS	9 Months Ended
	Aug. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	NOTE 7. STOCK COMPENSATION PLANS
	On July 11, 2011, at the Company’s Annual Meeting of Stockholders, the stockholders approved an amendment to increase the number of shares reserved under the 2004 Equity Incentive Plan (the “2004 Plan”) to a total of 70,974,213 shares. Additionally, an annual increase in the number of shares reserved under the plan was approved and certain prior increases in the number of shares reserved for issuance under the plan were ratified. Furthermore, on each of December 1, 2011 and on December 1, 2012, the number of shares reserved under the 2004 Plan was increased by an additional 1,500,000 shares pursuant to the provisions of the 2004 Plan. The purpose of the 2004 Plan is to provide a means by which eligible recipients of stock awards may be given the opportunity to benefit from increases in the value of the Company’s common stock through granting of incentive stock options (ISO), non-statutory stock options, stock purchase awards, stock bonus awards, stock appreciation rights, stock unit awards and other stock awards. As amended, there are 22,074,710 shares of common stock available for future awards under the 2004 Plan at August 31, 2013.
	GAAP treatment for stock options requires the recognition of the cost of employee services received in exchange for an award of equity instruments in the financial statements, which is measured based on the grant date fair value of the award, and requires the stock option compensation expense to be recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period), net of estimated forfeitures. The estimation of forfeitures requires significant judgment, and to the extent actual results or updated estimates differ from the current estimates, such resulting adjustment will be recorded in the period estimates are revised. No income tax benefit has been recognized for stock-based compensation arrangements and no compensation cost has been capitalized in the consolidated balance sheets.
	A summary of the status of stock options granted by MultiCell at August 31, 2013, and changes during the nine months then ended is presented in the following table:
						Weighted
				Weighted		Average
		Shares		Average		Remaining		Aggregate
		Under		Exercise		Contractual		Intrinsic
		Option		Price		Life		Value
	Outstanding at November 30, 2012		26,068,947	$	0.0084		3.1 years	$	-
	Granted		30,000,000		0.0011
	Exercised		-		-
	Expired or forfeited		-5,669,444		0.009
	Outstanding at August 31, 2013		50,399,503	$	0.004		3.9 years	$	3,000
	Exercisable at August 31, 2013		19,017,559	$	0.0086		2.2 years	$	-
	On August 16, 2013, the MultiCell Board of Directors granted an option to each of the five members of its Board of Directors to purchase 5,000,000 shares of the Company’s common stock at $0.0011 per share. The options vest quarterly over one year, subject to continuing service as a director on each such vesting date, and expire five years after grant. Additionally, the Board of Directors granted an option to an employee to purchase 5,000,000 shares of common stock at $0.0011 per share. This option vests monthly over three years, subject to continuing service as an employee on each such vesting date, and expires five years after grant. On June 1, 2012, the MultiCell Board of Directors granted an option to each of the five members of its Board of Directors to purchase 1,000,000 shares of the Company’s common stock at $0.0032 per share, the closing price of the Company’s common stock on the date of grant. The options vest quarterly over one year, subject to continuing service as a director on each such vesting date, and expire five years after grant. Additionally, the Board of Directors granted an option to an employee to purchase 1,000,000 shares of common stock at $0.0032 per share. This option vests monthly over three years, subject to continuing service as an employee on each such vesting date, and expires five years after grant. The fair value of stock option grants is estimated on the date of grant using the Black-Scholes option pricing model. The weighted-average fair value of stock options granted during the nine months ended August 31, 2013 was $0.0011 per share. The weighted-average assumptions used for options granted during the nine months ended August 31, 2013 were risk-free interest rate of 1.60%, volatility of 175%, expected life of 5.0 years, and dividend yield of zero. The weighted-average fair value of stock options granted during the nine months ended August 31, 2012 was $0.0030 per share. The weighted-average assumptions used for options granted during the nine months ended August 31, 2012 were risk-free interest rate of 0.62%, volatility of 170%, expected life of 5.0 years, and dividend yield of zero. The assumptions employed in the Black-Scholes option pricing model include the following: (i) the expected life of stock options represents the period of time that the stock options granted are expected to be outstanding prior to exercise; (ii) the expected volatility is based on the historical price volatility of the Company’s common stock; (iii) the risk-free interest rate represents the U.S. Treasury Department’s constant maturities rate for the expected life of the related stock options; and (iv) the dividend yield represents anticipated cash dividends to be paid over the expected life of the stock options.
	For the three months ended August 31, 2013 and 2012, MultiCell reported stock-based compensation expense for services related to stock options of $1,893 and $9,521, respectively. For the nine months ended August 31, 2013 and 2012, MultiCell reported stock-based compensation expense for services related to stock options of $10,705 and $32,759, respectively. As of August 31, 2013, there is approximately $35,000 of unrecognized compensation cost related to stock-based payments that will be recognized over a weighted average period of approximately 1.4 years. The intrinsic values at August 31, 2013 are based on a closing price of $0.0012.
	In October 2010, Xenogenics adopted the 2010 Stock Incentive Plan (the “2010 Plan”) which authorized the granting of stock awards to Xenogenics’ employees, directors, and consultants. As originally adopted, the 2010 Plan provided that the number of shares of Xenogenics’ common stock that could be issued pursuant to stock awards could not exceed 5,000,000 shares of common stock. On February 3, 2011, the 2010 Plan was amended such that the number of shares of Xenogenics’ common stock that could be issued pursuant to stock awards could not exceed 8,000,000 shares of common stock. The purpose of the 2010 Plan is to provide a means by which eligible recipients of stock awards may be given the opportunity to benefit from increases in the value of Xenogenics’ common stock through granting of incentive stock options (“ISO”), non-statutory stock options, stock bonus awards, stock appreciation rights, and rights to acquire restricted stock. ISO’s may be granted only to employees. The exercise price of each ISO granted under the plan must equal 100% of the market price of Xenogenics’ stock on the date of the grant. A 10% stockholder shall not be granted an ISO unless the exercise price of such option is at least 110% of the fair market value of Xenogenics’ common stock on the date of the grants and the option is not exercisable after the expiration of five years from the date of the grant. The Board of Directors of Xenogenics, in its discretion, shall determine the exercise price of each nonstatutory stock option. An option’s maximum term is 10 years.
	In November 2010, Xenogenics granted an option to a prospective executive officer to purchase an aggregate of 2,500,000 shares of its common stock, exercisable at $0.246 per share of common stock and having an expiration date in November 2015. The option to acquire 500,000 of the shares vested on the grant date and the remaining 2,000,000 shares vest in the future upon the achievement of specified milestones. The fair value of these options was estimated to be $576,250, or $0.2305 per share, as estimated using the Black-Scholes option-pricing model, using a risk-free interest rate of 1.23%, volatility of 165%, expected life of five years, and dividend yield of zero.
	In March 2011, Xenogenics granted options to other prospective officers and to the members of its scientific advisory board to purchase an aggregate of 3,000,000 shares of its common stock, exercisable at $0.246 per share of common stock and having a term of approximately five years. 50% of the options vested immediately and the remaining 50% were to vest upon the closing of a Qualified Financing by December 31, 2011. A “Qualified Financing” meant a single sale, or a related series of sales, by Xenogenics of its common stock (or common stock equivalents) in which the aggregate gross proceeds (before costs and commissions) received by Xenogenics was equal to or exceed $5,000,000. The fair value of these options was estimated to be $692,700, or $0.2309 per share, as estimated using the Black-Scholes option-pricing model, using a risk-free interest rate of 2.20%, volatility of 165%, expected lives of five years, and dividend yield of zero. A Qualified Financing was not closed by December 31, 2011, and accordingly, options to acquire 1,500,000 shares of Xenogenics common stock were forfeited. As described in the following paragraph, Xenogenics granted replacement options to four of five of these individuals whose options expired on December 31, 2011. The replacement of the options to the four individuals was treated as a modification under GAAP. The forfeiture of the option to the fifth individual resulted in the reversal of $57,725 of previously-recognized stock-based compensation expense in the three months ended February 29, 2012.
	On February 28, 2012, Xenogenics granted replacement options to four of five of those individuals whose options expired on December 31, 2011, as described in the previous paragraph. The replacement options to purchase 1,250,000 shares of Xenogenics’ common stock are exercisable at $0.253 per share and vest monthly over one year. These replacement options have a term of five years, provided a Qualified Financing has closed by February 28, 2013. No Qualified Financing closed by February 28, 2013. Consequently, these replacement options expired on February 28, 2013. The fair value of these options was estimated to be $298,500, or $0.2338 per share, as estimated using the Black-Scholes option-pricing model, using a risk-free interest rate of 0.84%, volatility of 170%, expected lives of five years, and dividend yield of zero.
	On July 28, 2013, Xenogenics granted an option to a consultant to purchase 500,000 shares of Xenogenics’ common stock at $0.246 per share. The option vests in equal increments of 125,000 on each of July 28, 2013, October 1, 2013, January 1, 2014, and April 1, 2014, subject to continuing service to Xenogenics on each such vesting date, and expires five years after grant. The fair value of these options was estimated to be $117,000, or $0.234 per share, as estimated using the Black-Scholes option-pricing model, using a risk-free interest rate of 1.37%, volatility of 175%, expected lives of five years, and dividend yield of zero.
	For the three months and nine months ended August 31 2013, Xenogenics reported stock-based compensation of $51,052 and $165,161, respectively. For the three months ended August 31, 2012, Xenogenics reported stock-based compensation expense for options of $95,925. For the nine months ended August 31, 2012, Xenogenics reported stock-based compensation expense for options of $251,128, less the reversal of previously recognized stock-based compensation in the amount of $57,725, for net stock-based compensation of $193,403. As of August 31, 2013, there is approximately $83,000 of unrecognized compensation cost related to stock-based payments that will be recognized over a weighted average period of approximately 0.5 years.

STOCK_WARRANTS

STOCK WARRANTS	9 Months Ended
	Aug. 31, 2013
Warrants and Rights Note Disclosure [Abstract]
Warrants Disclosure [Text Block]	NOTE 8. STOCK WARRANTS
	Since the Company’s inception, it has financed its operations primarily through the issuance of debt or equity instruments, which have often included the issuance of warrants to purchase shares of the Company’s common stock.
	As further described in Note 3 to these condensed consolidated financial statements, MultiCell entered into the LJCI Agreement pursuant to which MultiCell agreed to sell the Debenture in the principal amount of $100,000. In connection with the Debenture, MultiCell issued LJCI a warrant to purchase up to 10 million shares of the Company’s common stock at an exercise price of $1.09 per share, exercisable over the next five years according to a schedule described in a letter agreement dated February 28, 2007. Pursuant to the terms of the LJCI Warrant, upon the conversion of any portion of the principal amount of the Debenture, LJCI is required to simultaneously exercise and purchase that same percentage of the warrant shares equal to the percentage of the dollar amount of the Debenture being converted. Therefore, as an example, for each $1,000 of the principal of the Debenture converted, LJCI would be required to simultaneously purchase 100,000 shares under the warrant at $1.09 per share. During the nine months ended August 31, 2013, LJCI exercised warrants to purchase 943,000 shares of the Company’s common stock, resulting in proceeds to the Company of $1,027,870. During the nine months ended August 31, 2012, LJCI exercised warrants to purchase 729,000 shares of the Company’s common stock, resulting in proceeds to the Company of $794,610.
	A summary of the status of warrants at August 31, 2013, and changes during the nine months then ended is presented in the following table:
						Weighted
				Weighted		Average
		Shares		Average		Remaining		Aggregate
		Under		Exercise		Contractual		Intrinsic
		Warrants		Price		Life		Value
	Outstanding at November 30, 2012		9,277,030	$	0.7535		2.2 years	$	-
	Issued		-		-
	Exercised		-943,000		1.09
	Expired		-360,000		0.5
	Outstanding at August 31, 2013		7,974,030	$	0.7251		1.7 years	$	-

LOSS_PER_SHARE

LOSS PER SHARE	9 Months Ended
	Aug. 31, 2013
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]
	NOTE 9. LOSS PER SHARE
	Basic loss per share is computed on the basis of the weighted-average number of shares of the Company’s common stock outstanding during the period. Diluted loss per share is computed on the basis of the weighted-average number of shares of the Company’s common stock and all dilutive potentially issuable shares of the Company’s common stock outstanding during the year. Shares of the Company’s common stock issuable upon conversion of debt and preferred stock, or exercise of stock options and stock warrants have not been included in the loss per share for the three months and the nine months ended August 31, 2013 or 2012, as they are anti-dilutive.
	The potential shares of the Company’s common stock issuable upon exercise of options or warrants, or upon conversion of other convertible securities issued by the Company, as of August 31, 2013 and 2012, are as follows:
		2013		2012
	Warrants		7,974,030		9,963,030
	Stock options		50,399,503		24,168,947
	Series B Convertible Preferred Stock		27,806,452		47,049,793
	Series I Convertible Preferred Stock		-		2,293,600
	LJCI Debenture		5,819,876,621		6,055,511,583
			5,906,056,606		6,138,986,953
	MultiCell does not currently have sufficient authorized shares of its common stock to meet the commitments entered into under the Debenture and the related LJCI Warrants. As further discussed in Note 3, upon the conversion of any portion of the remaining $46,596 principal amount of the Debenture, LJCI is required to simultaneously exercise and purchase that same percentage of the remaining 4,659,629 warrant shares equal to the percentage of the dollar amount of the Debenture being converted. The agreement limits LJCI’s investment to an aggregate common stock ownership that does not exceed 9.99% of the outstanding shares of common stock of the Company. Furthermore, MultiCell has the right to redeem that portion of the Debenture that the holder may elect to convert and also has the right to redeem the outstanding principal amount of the Debenture not yet converted by the holder into common stock, plus accrued and unpaid interest thereon.

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS

9 Months Ended

Aug. 31, 2013

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

NOTE 10. FAIR VALUE MEASUREMENTS

For assets and liabilities measured at fair value, the Company uses the following hierarchy of inputs:

•

Level one — Quoted market prices in active markets for identical assets or liabilities;

•

Level two — Inputs other than level one inputs that are either directly or indirectly observable; and

•

Level three — Unobservable inputs developed using estimates and assumptions, which are developed by the Company and reflect those assumptions that a market participant would use.

Liabilities measured at fair value on a recurring basis at August 31, 2013 and November 30, 2012, are summarized as follows:

August 31, 2013

November 30, 2012

Level 1

Level 2

Level 3

Total

Level 1

Level 2

Level 3

Total

Derivative liability

$

-

$

30,587

$

-

$

30,587

$

-

$

19,245

$

-

$

19,245

As further described in Note 4, the fair value of the derivative liability is determined using the Black-Scholes pricing model.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Aug. 31, 2013
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 11. SUBSEQUENT EVENTS
	Stock Issued for Conversion of Debenture and Exercise of Warrants
	As more fully discussed in Note 3 to these consolidated financial statements, MultiCell sold the Debenture to LJCI and issued LJCI a stock warrant in connection with the Debenture. During the period subsequent to August 31, 2013 through the date of issuance of the condensed consolidated financial statements, LJCI converted $1,000 of the Debenture into 122,122,222 shares of the Company’s common stock. Simultaneously with the conversions of the Debenture, LJCI was required to exercise warrants to purchase 100,000 shares of the Company’s common stock at $1.09 per share. The total proceeds from the exercise of the warrants were $109,000.
	Sponsored Research Agreement
	On September 27, 2013, MultiCell entered into a new sponsored research agreement with Anand Ghanekar, M.D., Ph.D, of the University Health Network’s Toronto General Hospital expanding the scope of the current research project with the University Health Network (“UHN”) to evaluate MCT-485 in animal models for the treatment of primary liver cancer (the “Ghanekar Agreement”). On July 5, 2011, the Company had previously entered into a sponsored research agreement with UHN pursuant to which UHN evaluated the Company’s product candidates, MCT-465 and MCT-485, in in vitro models for the treatment of primary liver cancer (the “UHN Agreement”). The mechanism of action of MCT-465 and MCT-485 and their potential selective effect on liver cancer stem cells were also evaluated. Under the terms of each of the Ghanekar Agreement and the UHN Agreement, the Company retains exclusive access to the research findings and intellectual property resulting from the research activities preformed by each of Dr. Ghanekar and UHN, respectively.
	Ideal  BioStent™ — Amendment of Foreclosure Sale Agreement
	On September 30, 2010, Xenogenics entered into a Foreclosure Sale Agreement (“Foreclosure Sale Agreement”). Pursuant to the Foreclosure Sale Agreement, Xenogenics acquired all of the sellers’ interests in certain bioabsorbable stent assets (known as “Ideal BioStent™”) and related technologies. Under the Foreclosure Sale Agreement, Xenogenics is also required to make cash payments totaling $4.3 million to the sellers based on the achievement of certain milestones at certain dates. None of these milestones were achieved as of September 30, 2013. Xenogenics’ obligations under the Foreclosure Sale Agreement had been previously extended pursuant to Amendments No. 1 and No. 2, dated September 30, 2011 and October 23, 2012, respectively. On October 11, 2013, Xenogenics entered into Amendment No. 3 to the Foreclosure Sale Agreement which further extended the deadlines for the achievement of these milestones under the Foreclosure Sale Agreement by an additional twelve months. Xenogenics is required to use good faith reasonable efforts to achieve these milestones. Failure to achieve any of these milestones could result in all milestone payments, totaling $4.3 million, becoming immediately due and payable.

ORGANIZATION_AND_NATURE_OF_OPE1

ORGANIZATION AND NATURE OF OPERATIONS, BASIS OF PRESENTATION, AND RECLASSIFICATIONS (Policies)	9 Months Ended
	Aug. 31, 2013
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	BASIS OF PRESENTATION
	The accompanying unaudited condensed consolidated financial statements and related notes of MultiCell and its subsidiaries have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial statements. Accordingly, they do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America (“GAAP”) for complete financial statements. In the opinion of management, all adjustments consisting of normal recurring adjustments considered necessary for a fair presentation have been included. It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended November 30, 2012, previously filed with the SEC. The results of operations for the three-month and nine-month periods ended August 31, 2013, are not necessarily indicative of the operating results for the fiscal year ending November 30, 2013. The condensed consolidated balance sheet as of November 30, 2012, has been derived from the Company’s audited consolidated financial statements.
Reclassification, Policy [Policy Text Block]	RECLASSIFICATIONS
	Certain amounts of operating expenses from the condensed consolidated statement of operations for the three months and the nine months ended August 31, 2012, have been reclassified in the current presentation to conform to the presentation of operating expenses for the three months and nine months ended August 31, 2013. These reclassifications had no effect on the total amount of operating expenses, on the amount of net loss, or on the basic and diluted loss per common share for the three months and the nine months ended August 31, 2012.

SERIES_B_CONVERTIBLE_PREFERRED1

SERIES B CONVERTIBLE PREFERRED STOCK (Tables)	9 Months Ended
	Aug. 31, 2013
Series B Convertible Preferred Stock [Abstract]
Fair Value, by Balance Sheet Grouping [Table Text Block]	The fair value of the conversion feature was estimated at $30,587 ($0.0011 per share of common stock) and $19,245 ($0.0012 per share of common stock) at August 31, 2013 and November 30, 2012, respectively, and has been estimated using the Black-Scholes option-pricing model using the following assumptions:
		August 31,			May 31,			February 28,			November 30,
		2013			2013			2013			2012
	Fair value of common stock	$	0.0012		$	0.0014		$	0.0038		$	0.0013
	Conversion price of preferred stock	$	0.0124		$	0.0151		$	0.019		$	0.0215
	Risk free interest rate		2.78	%		2.16	%		1.89	%		1.62	%
	Expected life		10 Years			10 Years			10 Years			10 Years
	Dividend yield		-			-			-			-
	Volatility		148	%		148	%		147	%		141	%

STOCK_COMPENSATION_PLANS_Table

STOCK COMPENSATION PLANS (Tables)	9 Months Ended
	Aug. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the status of stock options granted by MultiCell at August 31, 2013, and changes during the nine months then ended is presented in the following table:
						Weighted
				Weighted		Average
		Shares		Average		Remaining		Aggregate
		Under		Exercise		Contractual		Intrinsic
		Option		Price		Life		Value
	Outstanding at November 30, 2012		26,068,947	$	0.0084		3.1 years	$	-
	Granted		30,000,000		0.0011
	Exercised		-		-
	Expired or forfeited		-5,669,444		0.009
	Outstanding at August 31, 2013		50,399,503	$	0.004		3.9 years	$	3,000
	Exercisable at August 31, 2013		19,017,559	$	0.0086		2.2 years	$	-

STOCK_WARRANTS_Tables

STOCK WARRANTS (Tables)	9 Months Ended
	Aug. 31, 2013
Warrants and Rights Note Disclosure [Abstract]
Schedule of Share-based Compensation Award, Shares Under Warrants [Table Text Block]	A summary of the status of warrants at August 31, 2013, and changes during the nine months then ended is presented in the following table:
						Weighted
				Weighted		Average
		Shares		Average		Remaining		Aggregate
		Under		Exercise		Contractual		Intrinsic
		Warrants		Price		Life		Value
	Outstanding at November 30, 2012		9,277,030	$	0.7535		2.2 years	$	-
	Issued		-		-
	Exercised		-943,000		1.09
	Expired		-360,000		0.5
	Outstanding at August 31, 2013		7,974,030	$	0.7251		1.7 years	$	-

LOSS_PER_SHARE_Tables

LOSS PER SHARE (Tables)	9 Months Ended
	Aug. 31, 2013
Earnings Per Share [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The potential shares of the Company’s common stock issuable upon exercise of options or warrants, or upon conversion of other convertible securities issued by the Company, as of August 31, 2013 and 2012, are as follows:
		2013		2012
	Warrants		7,974,030		9,963,030
	Stock options		50,399,503		24,168,947
	Series B Convertible Preferred Stock		27,806,452		47,049,793
	Series I Convertible Preferred Stock		-		2,293,600
	LJCI Debenture		5,819,876,621		6,055,511,583
			5,906,056,606		6,138,986,953

FAIR_VALUE_MEASUREMENTS_Tables

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
	Aug. 31, 2013
Fair Value Disclosures [Abstract]
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	Liabilities measured at fair value on a recurring basis at August 31, 2013 and November 30, 2012, are summarized as follows:
		August 31, 2013								November 30, 2012
		Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
	Derivative liability	$	-	$	30,587	$	-	$	30,587	$	-	$	19,245	$	-	$	19,245

ORGANIZATION_AND_NATURE_OF_OPE2

ORGANIZATION AND NATURE OF OPERATIONS, BASIS OF PRESENTATION, AND RECLASSIFICATIONS (Details Textual)	Aug. 31, 2013
Xenogenics Corporation [Member]
Equity Method Investment, Ownership Percentage	95.30%
Multicell Immunotherapeutics [Member]
Equity Method Investment, Ownership Percentage	67.00%

GOING_CONCERN_Details_Textual

GOING CONCERN (Details Textual) (USD $)	9 Months Ended
	Aug. 31, 2013	Nov. 30, 2012
Accumulated Deficit	$43,158,172	$42,254,594
Investment Warrants, Exercise Price	$1.09
La Jolla Cove Investors [Member]
Shares Remaining under Stock Warrant	4,659,629
Convertible Debt	46,596
Potential Proceeds from Warrant Exercises	$5,100,000
Debt Instrument, Convertible Percentage of Equity Instruments, Maximum	9.99%
Investment Warrants Expiration Date	28-Feb-14

CONVERTIBLE_DEBENTURES_Details

CONVERTIBLE DEBENTURES (Details Textual) (USD $)	9 Months Ended			9 Months Ended		0 Months Ended	12 Months Ended
	Aug. 31, 2013	Aug. 31, 2012	Nov. 30, 2012	Aug. 31, 2013	Aug. 31, 2012	Aug. 16, 2011	Nov. 30, 2007
				Common Stock [Member]	Common Stock [Member]	La Jolla Cove Investors [Member]	La Jolla Cove Investors [Member]
Securities Purchase, Agreement Date							28-Feb-07
Proceeds from Convertible Debenture, Principal Amount							$100,000
Debt Conversion, Original Debt, Due Date of Debt							28-Feb-12
Debt Instrument, Maturity Date						28-Feb-14
Debt Conversion, Original Debt, Interest Rate of Debt	4.75%	4.75%
Warrants Issued Number							10,000,000
Class of Warrant, Exercisable Period	5 years						5 years
Exercise of Warrant upon Conversion of Debt	each $1,000 of the principal converted, LJCI would be required to simultaneously purchase 100,000 shares under the LJCI Warrant at $1.09 per share.
Maximum Conversion Limit of Debt	The “Conversion Price” is equal to the lesser of $1.00 or 80% of the average of the three lowest volume-weighted average prices during the twenty trading days prior to the election to convert.
Stock Issued During Period, Value, Conversion of Convertible Securities	9,430	7,290
Stock Issued During Period, Shares, Conversion of Convertible Securities				1,040,493,584	323,936,571
Stock Issued During Period, Shares, Exercise of Warrants				943,000	729,000
Proceeds from Exercise of Stock Warrants	1,027,870	794,610
Advance from Warrant Holder	0		50,000
Convertible Debentures	46,596		0
Debt Conversion, Converted Instrument, Shares				5,800,000,000
Number of Warrants, Remaining Unexercised				4,659,629
Investment Warrants, Exercise Price	$1.09
Convertible Debt, Noncurrent	0		56,026
Receivable from Warrant Holder	$130,800

SERIES_B_CONVERTIBLE_PREFERRED2

SERIES B CONVERTIBLE PREFERRED STOCK (Details) (USD $)	3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Feb. 28, 2013	31-May-13	Aug. 31, 2013	Nov. 30, 2012
Fair value of common stock	$0.00	$0.00	$0.00	$0.00
Conversion price of preferred stock	$0.02	$0.02	$0.01	$0.02
Risk free interest rate	1.89%	2.16%	2.78%	1.62%
Expected life	10 years	10 years	10 years	10 years
Dividend yield	0.00%	0.00%	0.00%	0.00%
Volatility	147.00%	148.00%	148.00%	141.00%

SERIES_B_CONVERTIBLE_PREFERRED3

SERIES B CONVERTIBLE PREFERRED STOCK (Details Textual) (USD $)	3 Months Ended		9 Months Ended				9 Months Ended	12 Months Ended	9 Months Ended		12 Months Ended
	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2013	Aug. 31, 2012	Nov. 30, 2012	Aug. 31, 2013	Aug. 31, 2013	Nov. 30, 2012	Aug. 31, 2013	Aug. 31, 2013	Nov. 30, 2012
						Board of Directors Chairman [Member]	Series B Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Common Stock [Member]	Common Stock [Member]
									Maximum [Member]
Preferred Stock, Shares Designated	963,000		963,000		963,000	1,000,000	17,000	17,000
Preferred Stock, Purchase Price, Per Share, Value							$100
Preferred Stock, Conversion Price			$0.32
Reduced Conversion Price Percentage							85.00%
Preferred Stock Reduced Conversion Price							$0.01	$0.02
Conversion of Preferred Stock Limited to Common Stock, Outstanding, Percentage									9.99%
Preferred Stock, Dividend Payment Rate			Company was required to pay on each outstanding share of Series B convertible preferred stock a preferential cumulative dividend at an annual rate equal to the product of multiplying $100 per share by the higher of (i) the Wall Street Journal Prime Rate plus 1%, or (ii) 9%. In no event was the dividend rate to be greater than 12% per annum.
Preferred Stock, Dividend Rate, Maximum Percentage			12.00%
Dividends Payable	$290,724		$290,724		$290,724
Accounts Payable and Accrued Liabilities	165,208		165,208		165,208
Dividends Payable to Series B Convertible Preferred Stock	125,516		125,516		125,516
Preferred Stock, Shares Outstanding	0		0		0		3,448	3,448
Conversion of Convertible Preferred Stock Outstanding										27,806,452	16,037,209
Fair Value Conversion Feature	30,587		30,587		19,245
Fair Value of Embedded Conversion Feature, per share	$0.00		$0.00		$0.00
Gain (Loss) on Derivative Instruments, Net, Pretax	($902)	$60,562	($11,342)	$104,526

SERIES_I_CONVERTIBLE_PREFERRED1

SERIES I CONVERTIBLE PREFERRED STOCK (Details Textual)	Aug. 31, 2013	Nov. 30, 2012	Jul. 13, 2004	Aug. 31, 2013	Nov. 30, 2012	Aug. 31, 2013
			Accredited Investors [Member]	Series I Convertible Preferred Stock [Member]	Series I Convertible Preferred Stock [Member]	Board of Directors Chairman [Member]
Preferred Stock, Shares Designated	963,000	963,000		20,000	20,000	1,000,000
Preferred Stock, Shares Issued	0	0	20,000	0	0

LICENSE_AGREEMENTS_AND_DEFERRE1

LICENSE AGREEMENTS AND DEFERRED REVENUE (Details Textual) (USD $)	3 Months Ended		9 Months Ended
	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2013	Aug. 31, 2012
License and Purchase Agreement Description			On October 9, 2007, MultiCell executed an exclusive license and purchase agreement (the “Agreement”) with Corning Incorporated (“Corning”) of Corning, New York.
License and Maintenance Revenue			$750,000
Income Recognition Period			17 years
Deferred Revenue, Revenue Recognized	11,029	11,029	33,088	33,088
Deferred Revenue, Description			The balance of deferred revenue from this license is $488,971 at August 31, 2013 and will be amortized into revenue through October 2024.
Pfizer [Member]
Deferred Revenue, Revenue Recognized	$1,300	$1,300	$3,900	$3,900
Deferred Revenue, Description			The balance of deferred revenue from the agreement with Pfizer is $22,100 at August 31, 2013, which will be amortized into revenue through January 2018.

STOCK_COMPENSATION_PLANS_Detai

STOCK COMPENSATION PLANS (Details) (USD $)	9 Months Ended	12 Months Ended
	Aug. 31, 2013	Nov. 30, 2012
Shares Under Option, Outstanding, Beginning balance	26,068,947
Shares Under option, Granted	30,000,000
Shares Under Option, Exercised	0
Shares Under option, Expired or forfeited	-5,669,444
Shares Under Option,Outstanding, Ending balance	50,399,503	26,068,947
Shares Under Option,Exercisable	19,017,559
Weighted Average Exercise Price, Outstanding, Beginning balance	$0.01
Weighted Average Exercise Price,Granted (in dollars per share)	$0.00
Weighted Average Exercise Price, Exercised (in dollars per share)	$0
Weighted Average Exercise Price, Expired or forfeited (in dollars per share)	$0.01
Weighted Average Exercise Price, Outstanding, Ending balance	$0.00	$0.01
Weighted Average Exercise price,Exercisable (in dollars per share)	$0.01
Weighted Average Remaining Contractual Life, Outstanding	3 years 10 months 24 days	3 years 1 month 6 days
Weighted Average Remaining Contractual Life, Exercisable	2 years 2 months 12 days
Aggregate Intrinsic Value, Outstanding, Beginning balance	$0
Aggregate Intrinsic Value, Outstanding, Ending balance	3,000	0
Aggregate Intrinsic Value, Exercisable	$0

STOCK_COMPENSATION_PLANS_Detai1

STOCK COMPENSATION PLANS (Details Textual) (USD $)	3 Months Ended			6 Months Ended	9 Months Ended		12 Months Ended	3 Months Ended		9 Months Ended				12 Months Ended	1 Months Ended	3 Months Ended	9 Months Ended				1 Months Ended	3 Months Ended
	Aug. 31, 2013	Feb. 28, 2013	Aug. 31, 2012	31-May-13	Aug. 31, 2013	Aug. 31, 2012	Nov. 30, 2012	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2013	Aug. 31, 2012	Feb. 03, 2011	Oct. 31, 2010	Nov. 30, 2010	Mar. 31, 2011	Feb. 29, 2012	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2013	Aug. 31, 2012	Jul. 28, 2013	Feb. 29, 2012	Aug. 31, 2013	Dec. 02, 2012	Dec. 02, 2011	Jul. 11, 2011
								Xenogenics Corporation [Member]	Xenogenics Corporation [Member]	Xenogenics Corporation [Member]	Xenogenics Corporation [Member]	Xenogenics Corporation [Member]	Xenogenics Corporation [Member]	Executive Officer [Member]	Officers and Members of Scientific Advisory Board [Member]	Officers and Members of Scientific Advisory Board [Member]	Director [Member]	Director [Member]	Employee [Member]	Employee [Member]	Consultant [Member]	Replacement Options [Member]	Equity Incentive Plan 2004 [Member]	Equity Incentive Plan 2004 [Member]	Equity Incentive Plan 2004 [Member]	Equity Incentive Plan 2004 [Member]
														Xenogenics Corporation [Member]	Xenogenics Corporation [Member]	Xenogenics Corporation [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized												8,000,000	5,000,000											1,500,000	1,500,000	70,974,213
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant																							22,074,710
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					30,000,000									2,500,000	3,000,000		5,000,000	1,000,000	5,000,000	1,000,000	500,000	1,250,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price					$0.00									$0.25	$0.25		$0.00	$0.00	$0.00	$0.00	$0.25	$0.25
Share-based Compensation Arrangement by Share-based Payment Award, Award Term															5 years		5 years	5 years	5 years	5 years	5 years	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date														30-Nov-15
Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period Fair Value														$576,250	$692,700						$117,000	$298,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value					$0.00	$0.00								$0.23	$0.23						$0.23	$0.23
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		1.89%		2.16%	2.78%		1.62%							1.23%	2.20%		1.60%	0.62%			1.37%	0.84%
Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate		147.00%		148.00%	148.00%		141.00%							165.00%	165.00%		175.00%	170.00%			175.00%	170.00%
Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Term		10 years		10 years	10 years		10 years							5 years	5 years		5 years	5 years			5 years	5 years
Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate		0.00%		0.00%	0.00%		0.00%							0.00%	0.00%		0.00%	0.00%			0.00%	0.00%
Share-based Compensation, Total	52,945		105,446		175,866	226,162					251,128
Reversal Allocated Share-based Compensation Expense											57,725					57,725
Allocated Share-based Compensation Expense	1,893		9,521		10,705	32,759		51,052	95,925	165,161	193,403
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options	35,000				35,000			83,000		83,000
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition					1 year 4 months 24 days					6 months
Closing Price Share	$0.00				$0.00
Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Number														500,000
Share Based Compensation Arrangement By Share Based Payment Award Option Vested And Expected To Vest Outstanding Number														2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Percentage															50.00%
Stock Issuance Qualified Financing Milestone for Proceeds															$5,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period															1,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent										100.00%
Share-based Compensation Arrangement by Share-based Payment Award, Original Terms of Plan										10% stockholder shall not be granted an ISO unless the exercise price of such option is at least 110% of the fair market value of Xenogenics’ common stock on the date of the grants and the option is not exercisable after the expiration of five years from the date of the grant.
Share-based Compensation Arrangement by Share-based Payment Award, Option, Maximum Term										10 years

STOCK_WARRANTS_Details

STOCK WARRANTS (Details) (USD $)	9 Months Ended	12 Months Ended
	Aug. 31, 2013	Nov. 30, 2012
Shares Under Warrants, Outstanding , Beginning balance (in shares)	9,277,030
Shares Under Warrants, Issued (in shares)	0
Shares Under Warrants, Exercised (in shares)	-943,000
Shares Under Warrants, Expired (in shares)	-360,000
Shares Under Warrants, Outstanding, Ending balance (in shares)	7,974,030	9,277,030
Weighted Average Exercise Price, Outstanding, Beginning balance (in dollars per share)	$0.75
Weighted Average Exercise Price, Issued (in dollars per share)	$0
Weighted Average Exercise price, Exercised (in dollars per share)	$1.09
Weighted Average Exercise Price, Expired (in dollars per share)	$0.50
Weighted Average Exercise Price, Outstanding, Ending balance (in dollars per share)	$0.73	$0.75
Weighted Average Remaining Contractual Life, Outstanding	1 year 8 months 12 days	2 years 2 months 12 days
Aggregate Intrinsic Value, Outstanding, Beginning balance	$0
Aggregate Intrinsic Value, Outstanding, Ending balance	$0	$0

STOCK_WARRANTS_Details_Textual

STOCK WARRANTS (Details Textual) (USD $)	9 Months Ended
	Aug. 31, 2013	Aug. 31, 2012
Investment Warrants, Exercise Price	$1.09
Class of Warrant, Exercisable Period	5 years
Exercise of Warrant upon Conversion of Debt	each $1,000 of the principal converted, LJCI would be required to simultaneously purchase 100,000 shares under the LJCI Warrant at $1.09 per share.
Proceeds from Warrant Exercises	$130,800
La Jolla Cove Investors [Member]
Proceeds from Convertible Debenture, Principal Amount	100,000
Warrant Issued	10,000,000
Securities Purchase, Agreement Date	28-Feb-07
Exercise of Warrant upon Conversion of Debt	for each $1,000 of the principal of the Debenture converted, LJCI would be required to simultaneously purchase 100,000 shares under the warrant at $1.09 per share
Warrant Exercised to Purchase Common Stock, Shares	943,000	729,000
Proceeds from Warrant Exercises	$1,027,870	$794,610

LOSS_PER_SHARE_Details

LOSS PER SHARE (Details)	9 Months Ended
	Aug. 31, 2013	Aug. 31, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	5,906,056,606	6,138,986,953
Series B Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	27,806,452	47,049,793
Series I Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	2,293,600
LJCI Debenture [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	5,819,876,621	6,055,511,583
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	7,974,030	9,963,030
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	50,399,503	24,168,947

LOSS_PER_SHARE_Details_Textual

LOSS PER SHARE (Details Textual) (USD $)	Aug. 31, 2013	Nov. 30, 2012
Convertible Debentures	$46,596	$0
La Jolla Cove Investors [Member]
Remaining Number of Warrants Outstanding	4,659,629
Debt Instrument, Convertible Percentage of Equity Instruments, Maximum	9.99%

FAIR_VALUE_MEASUREMENTS_Detail

FAIR VALUE MEASUREMENTS (Details) (USD $)	Aug. 31, 2013	Nov. 30, 2012
Derivative liability	$30,587	$19,245
Fair Value, Inputs, Level 1 [Member]
Derivative liability	0	0
Fair Value, Inputs, Level 2 [Member]
Derivative liability	30,587	19,245
Fair Value, Inputs, Level 3 [Member]
Derivative liability	$0	$0

SUBSEQUENT_EVENTS_Details_Text

SUBSEQUENT EVENTS (Details Textual) (USD $)	9 Months Ended
	Aug. 31, 2013
Proceeds from Warrant Exercises	$130,800
Subsequent Event [Member]
Debt Conversion, Original Debt, Amount	1,000
Debt Conversion, Converted Instrument, Shares Issued	122,122,222
Warrant Exercised To Purchase Common Stock Shares	100,000
Warrants Exercise Price	$1.09
Proceeds from Warrant Exercises	109,000
Subsequent Event [Member] | Xenogenics Corporation [Member]
Required Payments Under Agreement	4,300,000
Contingent Liability Under Agreement	$4,300,000